VKTX240830C68000
- 1.26
- -0.77-37.93%
Viking Therapeutics Newsroom
Obesity Drugs' Next Wave: These Companies Could Snag 20% of GLP-1 Market, Analysts Say
Viking Therapeutics Stock Could Rocket 76% Higher According to Wall Street. Is It a Buy Now?
Why Viking Therapeutics Is Thriving in the $150 Billion Weight Loss Drug Market
Eli Lilly, Novo Nordisk to Maintain 'Two Horse Race' in GLP-1 Weight Loss Market
Director J Singleton Sells 5,700 Shares of Viking Therapeutics Inc (VKTX)
Viking Therapeutics Could Be a New Winner in the GLP-1 Space
(VKTX) - Analyzing Viking Therapeutics's Short Interest
Zacks Investment Ideas Feature Highlights: Viking Therapeutics, McDonalds, Starbucks, Novo Nordisk and Eli Lilly
Big Pharma Stocks: Who's Leading the Race and Who's Slipping?
Unpacking the Latest Options Trading Trends in Viking Therapeutics
Viking Therapeutics Stock Slips 4%
S&P 500 Futures Rise In Premarket Trading; Fabrinet, Amer Sports Lead
Viking Therapeutics Insider Sold Shares Worth $7,426,508, According to a Recent SEC Filing
Viking Therapeutics(VKTX.US) Officer Sells US$7.43 Million in Common Stock
Form 144 | Viking Therapeutics(VKTX.US) Officer Proposes to Sell 7.43 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Aug 19, $Viking Therapeutics(VKTX.US)$ Officer Lian Brian intends to sell 112.87K shares of its common stock on Aug 19, with a total market value of approximately $7.43
Director J Singleton Sells 16,000 Shares of Viking Therapeutics Inc (VKTX)
Viking Therapeutics Options Spot-On: On August 19th, 75,068 Contracts Were Traded, With 196.95K Open Interest
$100 Invested In This Stock 5 Years Ago Would Be Worth $800 Today
Could Viking Therapeutics Become the Next Novo Nordisk?
Why Is Viking Therapeutics, Inc. (VKTX) the Best Diabetes Stock to Buy Now?